Tumour stage |
T1 |
6 (45.1) |
32 (44.4) |
T2 |
43 (42.2) |
33 (45.8) |
T3 |
13 (12.7) |
7 (9.7) |
Lymph node stage |
N0 |
43 (42.2) |
31 (43.1) |
N1 |
38 (37.3) |
30 (41.7) |
N2 |
12 (11.8) |
9 (12.5) |
N3 |
9 (8.8) |
2 (2.8) |
Tumour subtype |
Luminal A-like |
12 (11.8) |
7 (9.7) |
Luminal B-like |
47 (46.1) |
35 (48.6) |
Luminal B HER2 positive |
19 (18.6) |
14 (19.4) |
HER2 positive |
8 (7.8) |
6 (8.3) |
Triple-negative |
16 (15.7) |
10 (13.9) |
Type of surgery |
Breast-conserving surgery + Sentinel node biopsy |
37 (36.3) |
28 (38.9) |
Breast-conserving surgery + Axillary dissection |
14 (13.7) |
11 (15.3) |
Mastectomy + Sentinel node biopsy |
23 (22.5) |
15 (20.8) |
Mastectomy + Axillary dissection |
28 (27.5) |
18 (25.0) |
Breast reconstruction |
None |
78 (76.5) |
55 (76.4) |
Deep inferior flap |
13 (12.7) |
10 (13.9) |
Tissue expander, followed by silicone implant |
11 (10.8) |
7 (9.7) |
Chemotherapy type |
Anthracyclines and taxanes |
70 (68.7) |
51 (70.8) |
Anthracyclines only |
19 (18.6) |
13 (18.1) |
Taxanes only |
10 (9.8) |
6 (8.3) |
CMF |
3 (2.9) |
2 (2.8) |
Anti-HER2 therapy |
27 (26.4) |
20 (27.8) |
Adjuvant endocrine therapy |
78 (76.5) |
57 (79.2) |
Radiotherapy |
81 (79.4) |
59 (81.9) |